A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

3 months ago 169

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Read Entire Article

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Related

Here are 7 charts guaranteed to stress you out about the sto...

More companies than usual are beating Wall Street’s expectat...

These ‘safer’ chip stocks have boomed this year. Is it too l...

Trending

Popular

CFTC expands payment stablecoin criteria to include national...

Broad-based bitcoin accumulation emerges after sharp capitul...

Over 23% of traders now expect interest rate cut at next FOM...

More companies than usual are beating Wall Street’s expectat...

'Massive consolidation' expected across crypto industry: Bul...

Ethereum Foundation teams up with SEAL to combat wallet drai...

Jack Dorsey’s Block may cut up to 10% of staff in business o...

Bitcoin remains in tight range under $70,000 ahead of Wednes...

ETH taps $2.1K as crypto, macro markets rebound: Is the bott...

Memory-chip stocks are still quite cheap — especially if you...